Delving into the Latest Updates on Miravirsen with Synapse

Overview

Basic Info

Drug Type

ASO

Synonyms

LNA-antimiR-122, Miravirsen sodium

+ [2]

Target

miR-122

Mechanism

miR-122 inhibitors(microRNA 122 inhibitors)

Therapeutic Areas

Infectious DiseasesDigestive System DisordersEye Diseases

Active Indication-

Inactive Indication

Chronic hepatitis C genotype 1Eye DiseasesHepatitis C+ [1]

Originator Organization

F. Hoffmann-La Roche Ltd.

Active Organization-

Inactive Organization

Roche Innovation Center Copenhagen A/S

Bausch & Lomb, Inc.

Drug Highest PhaseDiscontinuedPhase 2

First Approval Date-

Regulation-

Login to view timeline

Structure

Boost your research with our RNA technology data.

login

or

view full example data

Boost your research with our RNA technology data.

Gene Sequence

Sequence Code 29396213

Source: *****

Genotype 1 CHC participants from Study SPC3649-207 with null response to prior pegylated-interferon alpha plus ribavirin will be enrolled into this 36-month extension study, designed to evaluate the long-term safety and efficacy after 12 weeks of miravirsen monotherapy. Due to the observational nature of the study, miravirsen will not be dosed as an investigational product.

Start Date02 Aug 2013

Sponsor / Collaborator

Hoffmann-La Roche, Inc.

[+1]

NCT01872936 / Unknown statusPhase 2

Phase 2, Open-Label, Clinical Trial of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Null Responders to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C Virus Genotype 1 Infection

The purpose of this open-label study is to assess the safety, tolerability, antiviral activity, genotype resistance associated with virological failure, pharmacokinetics and pharmacodynamics of two dose regimens of miravirsen in combination with telaprevir and ribavirin in subjects with hepatitis C virus genotype 1 infection who are null responder to pegylated-interferon alpha and ribavirin.

Start Date01 Jun 2013

Sponsor / Collaborator

Roche Innovation Center Copenhagen A/S

100 Clinical Results associated with Miravirsen

Login to view more data

100 Translational Medicine associated with Miravirsen

Login to view more data

100 Patents (Medical) associated with Miravirsen

Login to view more data

42

Literatures (Medical) associated with Miravirsen

01 Nov 2024·Bioactive Materials

Framework nucleic Acid-MicroRNA mediated hepatic differentiation and functional hepatic spheroid development for treating acute liver failure

Article

Author: Wang, Haixia ; Ju, Enguo ; Li, Fenfang ; Li, Mingqiang ; Tao, Yu ; Xue, Tiantian ; Wei, Hongyan

The specific induction of hepatic differentiation presents a significant challenge in developing alternative liver cell sources and viable strategies for clinical therapy of acute liver failure (ALF). The past decade has witnessed the blossom of microRNAs in regenerative medicine. Herein, microRNA 122-functionalized tetrahedral framework nucleic acid (FNA-miR-122) has emerged as an unprecedented and potential platform for directing the hepatic differentiation of adipose-derived mesenchymal stem cells (ADMSCs), which offers a straightforward and cost-effective method for generating functional hepatocyte-like cells (FNA-miR-122-iHep). Additionally, we have successfully established a liver organoid synthesis strategy by optimizing the co-culture of FNA-miR-122-iHep with endothelial cells (HUVECs), resulting in functional Hep:HUE-liver spheroids. Transcriptome analysis not only uncovered the potential molecular mechanisms through which miR-122 influences hepatic differentiation in ADMSCs, but also clarified that Hep:HUE-liver spheroids could further facilitate hepatocyte maturation and improved tissue-specific functions, which may provide new hints to be used to develop a hepatic organoid platform. Notably, compared to transplanted ADMSCs and Hep-liver spheroid, respectively, both FNA-miR-122-iHep-based single cell therapy and Hep:HUE-liver spheroid-based therapy showed high efficacy in treating ALF in vivo. Collectively, this research establishes a robust system using microRNA to induce ADMSCs into functional hepatocyte-like cells and to generate hepatic organoids in vitro, promising a highly efficient therapeutic approach for ALF.

01 Jan 2021·Frontiers in Bioscience-Scholar

Role of noncoding RNAs in Dengue virushost interaction

Review

Author: Bhattacharyya, Sankar ; Srivastava, Rupesh K ; Kaur, Jaskaran ; Y S, Ravi Kumar ; Pandey, Kush Kumar ; Rawat, Yogita ; Sapra, Leena ; Madhry, Deeksha ; Verma, Bhupendra

Dengue is potentially a life-threatening arthropod-borne viral infection for which there are no known therapeutic agents till date. Early stage diagnosis of dengue infection is still lacking. Diagnosis is only made after severe manifestations and later stages of infection. Timely prognosis can prevent dengue related mortalities. The nucleic acid-based therapy has potential to emerge as a promising approach for early diagnosis and treatment of this viral infection. Many studies have been carried out suggested the regulatory role of ncRNAs thereby revealing the importance of protein-RNA and RNA-RNA interactions during infection. Various regulatory RNAs are either expressed by mammalian cells or generated by viral RNA have reported to play important roles in viral life cycle including dengue virus. Thus exploring host-virus interaction will pave the novel path for understanding the pathophysiology of febrile infection in dengue. Rapid advances in sequencing techniques along with significant developments in the field of RNA studies has made RNA therapeutics as one of the promising approaches as antiviral targets. The idea of RNA based therapies has been greatly backed by a Hepatitis C virus drug, Miravirsen which has successfully completed phase II clinical trial. In the present review, we will discuss the implications of different non-coding RNAs in dengue infection. Differential expression of small ncRNA may serve as a reliable biomarker of disease severity during different stages of infection and can also play regulatory roles in disease progression.

01 Dec 2020·Journal of Biomedical ScienceQ2 · MEDICINE

Role of microRNAs in antiviral responses to dengue infection

Q2 · MEDICINE

ReviewOA

Author: Affendi, Sarah ; Wong, Rui Rui ; Abd-Aziz, Noraini ; Poh, Chit Laa

AbstractDengue virus (DENV) is the etiological agent of dengue fever. Severe dengue could be fatal and there is currently no effective antiviral agent or vaccine. The only licensed vaccine, Dengvaxia, has low efficacy against serotypes 1 and 2. Cellular miRNAs are post-transcriptional regulators that could play a role in direct regulation of viral genes. Host miRNA expressions could either promote or repress viral replications. Induction of some cellular miRNAs could help the virus to evade the host immune response by suppressing the IFN-α/β signaling pathway while others could upregulate IFN-α/β production and inhibit the viral infection. Understanding miRNA expressions and functions during dengue infections would provide insights into the development of miRNA-based therapeutics which could be strategized to act either as miRNA antagonists or miRNA mimics. The known mechanisms of how miRNAs impact DENV replication are diverse. They could suppress DENV multiplication by directly binding to the viral genome, resulting in translational repression. Other miRNA actions include modulation of host factors. In addition, miRNAs that could modulate immunopathogenesis are discussed. Major hurdles lie in the development of chemical modifications and delivery systems for in vivo delivery. Nevertheless, advancement in miRNA formulations and delivery systems hold great promise for the therapeutic potential of miRNA-based therapy, as supported by Miravirsen for treatment of Hepatitis C infection which has successfully completed phase II clinical trial.

100 Deals associated with Miravirsen

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Miravirsen	-	DB12851

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic hepatitis C genotype 1	Phase 2	PR	Roche Innovation Center Copenhagen A/S	01 Nov 2012
Hepatitis C, Chronic	Phase 2	DE	Roche Innovation Center Copenhagen A/S	01 Sep 2010
Hepatitis C, Chronic	Phase 2	SK	Roche Innovation Center Copenhagen A/S	01 Sep 2010
Hepatitis C, Chronic	Phase 2	PL	Roche Innovation Center Copenhagen A/S	01 Sep 2010
Hepatitis C, Chronic	Phase 2	NL	Roche Innovation Center Copenhagen A/S	01 Sep 2010
Hepatitis C	Phase 2	DK	Roche Innovation Center Copenhagen A/S	01 May 2008
Eye Diseases	Phase 2	US	Bausch & Lomb, Inc.	01 Sep 2006